

China Biologic Products, Inc.  
Form 8-K  
July 15, 2011

---

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**  
Washington, D.C. 20549

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

Date of Report (Date of Earliest event Reported): July 15, 2011

**CHINA BIOLOGIC PRODUCTS, INC.**

*(Exact name of registrant as specified in its charter)*

**Delaware**  
*(State or other jurisdiction of  
incorporation or organization)*

**001-34566**  
*(Commission File No.)*

**75-2308816**  
*(IRS Employer ID No.)*

**No. 14 East Hushan Road,  
Tai'an City, Shandong, 271000  
People's Republic of China**  
*(Address of Principal Executive Offices)*  
**86-538 -620-2306**  
*Registrant's telephone number, including area code*

---

*(Former name or former address, if changed since last report)*

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a -12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d -2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e -4(c))
-

**Item 8.01. Other Events**

On July 15, 2011, China Biologic Products, Inc. issued a press release relating to the revised Plan for Guizhou Provincial Blood Collection Institutional Setting (2011-2014) issued by the Guizhou Provincial Health Bureau. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

**Item 9.01 Financial Statements and Exhibits.**

(d) Exhibits

**Exhibit No. Description**

Exhibit No.	Description
<u>99.1</u>	<u>Press Release dated July 15, 2011</u>

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: July 15, 2011

**CHINA BIOLOGIC PRODUCTS, INC.**

By: /s/ Chao Ming Zhao  
Chao Ming Zhao  
Chief Executive Officer

---

**EXHIBIT INDEX**

**Exhibit No. Description**

99.1      Press Release dated July 15, 2011

---